ArticleJournal of translational medicine2026
DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) is an incurable plasma cell malignancy. Dyskerin pseudouridine synthase 1 (DKC1), a nucleolar protein, is essential for RNA modification and cellular homeostasis, yet its role in MM remains unclear.
methodsPrognostic significance of DKC1 in MM patients was evaluated using the MMRF CoMMpass and GEO datasets. Functional effects of DKC1 knockdown or overexpression were investigated via in vitro proliferation, apoptosis assays and in vivo xenografts. Transcriptomic profiling and CMC-based pseudouridine (Ψ) mapping were used to define DKC1-mediated regulation of ATF5.
resultsElevated DKC1 expression was identified as an independent prognostic marker of poor outcomes in MM patients. Decision tree analysis demonstrated that integrating DKC1 expression further refined prognostic stratification beyond the ISS system. Functional assays revealed that DKC1 promoted MM cell proliferation, survival and colony formation, while DKC1 knockdown or pharmacologic inhibition with pyrazofurin significantly reduced MM cell proliferation and colony formation, increased apoptosis in vitro, and suppressed tumor growth in xenograft models. RNA sequencing analysis identified ATF5 as a downstream target of DKC1, and subsequent experimental validation confirmed that DKC1 exerts part of its function through ATF5. We further demonstrated that DKC1 knockdown reduces ATF5 mRNA stability through impaired pseudouridylation. Site-specific Ψ modifications on ATF5 mRNA confirmed a direct post-transcriptional regulatory mechanism.
conclusionsDKC1 drives MM progression by promoting ATF5 stability through pseudouridylation, thereby enhancing myeloma cell proliferation and survival. These findings highlight that DKC1 may be used as a potential biomarker for risk stratification and a promising therapeutic target in MM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.